EUS Guided Celiac Neurolysis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2009
* Hypothesis: - Direct CGN enhances neurolytic drug delivery into celiac ganglia and increases the efficacy of neurolysis and subsequent pain control and survival in patients with pancreatic carcinoma. * Rationale: * Standard CPN leads to inaccurate delivery of the injectate with rapid dispersal thereby only briefly remaining in contact with neural structures and limiting the degree of neurolysis. Poor targeting and delivery of a neurolytic agent may result in diminished neurolysis and decrease efficacy.
Epistemonikos ID: 1971502f0f229fc071079af45e16d19e3b9c88ef
First added on: May 11, 2024